Kinaset Therapeutics
MEDFIELD, MA · Healthcare, Health Care · 9 employees
Kinaset Therapeutics is a clinical-stage biotechnology company focused on developing novel respiratory therapies for patients with intractable diseases, combining an experienced team with a potentially best-in-class approach to treating severe asthma.
Funding history
- Series SERIES B — $103.0M — Jan 2026
- Funding Round — $28.5M — Jul 2023
- Funding Round — $28.5M — Jul 2022
- Funding Round — $28.5M — Aug 2020
Recent signals
- Jan 10, 2026: Raised $103.0M in Series SERIES B
- Jan 29, 2025: Launched Kinaset Therapeutics Announces FDA Clearance for frevecitinib in the Treatment of Asthma.
- Jul 17, 2023: Raised $28.5M
- Jul 18, 2022: Raised $28.5M
- Aug 17, 2020: Raised $28.5M
See plans & pricing → Track Kinaset Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.